Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Fase Phase 1, Phase 2	Date Added 2020-11-12	Ubicación California, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States Francia Israel Países Bajos Polonia España Turkey	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas cemiplimab, REGN7075	Etiquetas MSS/ MMRp
NCT ID NCT01174121	TitleImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Fase Fase 2	Date Added 2010-08-03	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Fase Fase 1	Date Added 2021-11-04	Ubicación California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas NX-1607	Etiquetas MSS/ MMRp
NCT ID NCT02693535	TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Fase Fase 2	Date Added 2016-02-26	Ubicación Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04111458	TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	Fase Fase 1	Date Added 2019-10-01	Ubicación Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Alemania Países Bajos	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas BI 1701963, Trametinib	Etiquetas MSS/ MMRp
NCT ID NCT04575922	TitleNivolumab+Ipilimumab+RT in MSS mCRC	Fase Fase 2	Date Added 2020-10-05	Ubicación Massachusetts, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT03088150	TitleEnsayo COLLISION - Metástasis hepáticas colorrectales: Cirugía frente a ablación térmica	Fase Fase 3	Date Added 2017-03-23	Ubicación Países Bajos	Prior IO Allowed Sí	CRC-directed Sí	Status Unknown status	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05213195	TitleTerapia celular NKG2D CAR-NK en pacientes con cáncer colorrectal metastásico refractario	Fase Fase 1	Date Added 2022-01-28	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas NKG2D CAR-NK	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03190941	TitleAdministración de linfocitos de sangre periférica transducidos con un receptor murino de células T que reconoce la variante G12V del RAS mutado en pacientes HLA-A*11:01	Fase Phase 1, Phase 2	Date Added 2017-06-19	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03785249	TitleEstudio de fase 1/2 de MRTX849 en pacientes con cáncer que presentan una mutación KRAS G12C KRYSTAL-1	Fase Fase 1	Date Added 2018-12-24	Ubicación Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas afatinib, cetuximab, MRTX849, Pembrolizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 71 to 80 of 299 entries